OncoMatch/Clinical Trials/NCT03909412
Carfilzomib Based Chemotherapy Mobilization for Autologous Stem Cell Transplants in Multiple Myeloma
Is NCT03909412 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies multiple treatments including Carfilzomib and Cyclophosphamide for multiple myeloma.
Treatment: Carfilzomib · Cyclophosphamide · Dexamethasone · Granulocyte Colony-Stimulating Factor — This phase I study utilizes a 3+3 design with escalating cohorts of Carfilzomib at 20mg/m2, 27mg/m2, 36mg/m2, 45mg/m2, 56mg/m2, and 70mg/m2 to be administered concomitantly with Cyclophosphamide 2 gm/m2, Dexamethasone and Granulocyte colony-stimulating factor (G-CSF)
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Chemotherapy
Other
Cancer type
Multiple Myeloma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: proteasome inhibitor (carfilzomib)
Subject previously received treatment with Carfilzomib.
Must have received: induction therapy
Subjects must have completed any 'induction therapy' and have achieved less than a CR.
Cannot have received: stem cell transplant
Subject has had prior mobilization or stem cell transplant.
Cannot have received: radiation therapy
Exception: Enrollment of subjects who require concurrent radiotherapy (which must be localized in its field size) should be deferred until the radiotherapy is completed and 3 weeks have elapsed since the last date of therapy.
Subject has received radiation therapy within 3 weeks of enrollment.
Lab requirements
Blood counts
Absolute neutrophil count (ANC) ≥1000 cells/mm3 (≥500 for patients with bone marrow biopsy displaying >50% involvement by myeloma); Platelets count ≥ 50,000/mm3 (≥ 30,000 for patients with bone marrow biopsy displaying >50% involvement by myeloma); Hemoglobin > 9.0 g/dL
Liver function
Serum SGOT/AST <3.0 x ULN; Serum SGPT/ALT <3.0 x ULN; Serum total bilirubin <1.5 x ULN
Cardiac function
MUGA scan or echo with LVEF ≥40% within 6 months of enrollment
Absolute neutrophil count (ANC) ≥1000 cells/mm3 (≥500 for patients with bone marrow biopsy displaying >50% involvement by myeloma); Platelets count ≥ 50,000/mm3 (≥ 30,000 for patients with bone marrow biopsy displaying >50% involvement by myeloma); Hemoglobin > 9.0 g/dL; Serum SGOT/AST <3.0 x ULN; Serum SGPT/ALT <3.0 x ULN; Serum total bilirubin <1.5 x ULN; MUGA scan or echo with LVEF ≥40% within 6 months of enrollment.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Hackensack Meridian Health - John Theurer Cancer Center · Hackensack, New Jersey
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT03909412 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior stem cell transplant, radiation therapy disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages